24/7 Market News Snapshot 15 May, 2025 – Rocket Pharmaceuticals, Inc. Common Stock (NASDAQ:RCKT)

May 15, 2025

DENVER, Colo., 15 May, 2025 (www.247marketnews.com) – (NASDAQ:RCKT) are discussed in this article.
Rocket Pharmaceuticals, Inc. (RCKT) has recently shown commendable market performance, opening at $6.01 and trading up to $6.685, reflecting a substantial gain of 10.40% as investor enthusiasm grows. The previous day’s close was recorded at $6.055, indicating a positive change in market sentiment. A notable trading volume of 6.41 million shares has been observed, signaling heightened engagement from investors and the potential for bullish trends. Analysts suggest that crucial resistance levels may materialize around $6.75, while support is indicated near the opening price. Carefully monitoring these levels will be essential as a breakout could signify further upward mobility for RCKT.

In conjunction with the robust trading activity, Rocket Pharmaceuticals released promising preliminary data from a Phase 1 clinical trial of RP-A601, an investigational gene therapy targeting plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM). The data, presented at the recent Annual Meeting of the American Society of Gene and Cell Therapy, showcases a well-tolerated safety profile, with no dose-limiting toxicities noted in a cohort of three patients monitored for up to 12 months.

The intravenous infusion of RP-A601 has resulted in a significant uptick in PKP2 protein expression levels. Patients have reported vital improvements in heart functions and overall quality of life, with stabilization or reduction in arrhythmia burden. Notably, all subjects demonstrated normalization of right ventricular function, alongside meaningful enhancements in quality-of-life assessments and reductions in ventricular ectopy.

Dr. Gaurav Shah, CEO of Rocket Pharmaceuticals, expressed optimism regarding these findings, describing the results as “highly encouraging” and signaling substantial potential for clinical benefit. This breakthrough exemplifies Rocket’s commitment to delivering innovative solutions for patients afflicted with rare heart conditions and underscores ongoing advancements in their gene therapy portfolio.

Related news for (RCKT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.